Mesenchymal stem cell may reduce GVHD in transplant patients

03/28/2008 | Australian Life Scientist

Worldwide trials are testing mesenchymal stem cells to battle graft-versus-host disease. The stem cells seem to have anti-inflammatory and immuno-modulatory abilities. "In terms of laboratory tests they have been shown to inhibit different aspects of the immune response, such as T cell responses, they inhibit cytokine production and they also inhibit dendritic cells," said one expert.

View Full Article in:

Australian Life Scientist

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC